How I evaluate and treat resistance and relapse in CML

Area of Science:

• Hematology
• Oncology
• Pharmacology

Background:

• Chronic myeloid leukemia (CML) treatment has advanced significantly with tyrosine kinase inhibitors (TKIs), leading to excellent survival outcomes.
• Treatment challenges arise when patients do not meet or lose response milestones, necessitating careful therapeutic reassessment.
• A range of TKIs are available for different treatment lines, each with unique mechanisms, potencies, resistance profiles, and tolerability.

Purpose of the Study:

• To provide practical guidance for therapeutic reassessment in CML patients.
• To detail essential laboratory investigations and clinical considerations for decision-making.
• To assist clinicians in making informed choices regarding TKI sequencing and potential stem cell transplantation.

Main Methods:

• Review of current literature and clinical guidelines on CML treatment and TKI resistance.
• Discussion of criteria for defining and assessing treatment resistance.
• Integration of clinical and biological factors for personalized treatment strategies.

Main Results:

• Resistance to TKIs is defined by specific molecular and clinical criteria.
• Therapeutic reassessment involves comprehensive laboratory testing (e.g., BCR-ABL kinase domain mutation analysis) and clinical evaluation.
• Sequencing of TKIs and consideration of allogeneic stem cell transplant depend on individual patient profiles and treatment history.

Conclusions:

• Individualized treatment strategies are crucial for managing CML, as 'one-size-fits-all' approaches are inadequate.
• Careful integration of laboratory data and clinical factors is essential for optimizing TKI therapy and patient outcomes.
• Informed decision-making regarding TKI sequencing and transplant can rescue optimal responses in CML patients.